Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Ryan K. Shields; Erin K. McCreary; Rachel V. Marini; Ellen G. Kline; Chelsea E. Jones; Binghua Hao; Liang Chen; Barry N. Kreiswirth; Yohei Doi; Cornelius J. Clancy; M. Hong Nguyen

doi:10.1093/cid/ciz1131

Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Ryan K. Shields
, Erin K. McCreary
, Rachel V. Marini
, Ellen G. Kline
, Chelsea E. Jones
, Binghua Hao
, Liang Chen
, Barry N. Kreiswirth
, Yohei Doi
, Cornelius J. Clancy
, M. Hong Nguyen

Research output: Contribution to journal › Article › peer-review

83 Citations (Scopus)

Abstract

Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

Original language	English
Pages (from-to)	667-671
Number of pages	5
Journal	Clinical Infectious Diseases
Volume	71
Issue number	3
DOIs	https://doi.org/10.1093/cid/ciz1131
Publication status	Published - 01-08-2020
Externally published	Yes

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciz1131

Cite this

@article{4fd3c07041154441bfde9a924498c076,

title = "Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections",

abstract = "Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65\% (13/20) and 90\% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.",

keywords = "KPC, Meropenem, P orin, Resistance, Vaborbactam",

author = "Shields, \{Ryan K.\} and McCreary, \{Erin K.\} and Marini, \{Rachel V.\} and Kline, \{Ellen G.\} and Jones, \{Chelsea E.\} and Binghua Hao and Liang Chen and Kreiswirth, \{Barry N.\} and Yohei Doi and Clancy, \{Cornelius J.\} and Nguyen, \{M. Hong\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2019.",

year = "2020",

month = aug,

day = "1",

doi = "10.1093/cid/ciz1131",

language = "English",

volume = "71",

pages = "667--671",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

AU - Shields, Ryan K.

AU - McCreary, Erin K.

AU - Marini, Rachel V.

AU - Kline, Ellen G.

AU - Jones, Chelsea E.

AU - Hao, Binghua

AU - Chen, Liang

AU - Kreiswirth, Barry N.

AU - Doi, Yohei

AU - Clancy, Cornelius J.

AU - Nguyen, M. Hong

N1 - Publisher Copyright: © The Author(s) 2019.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

AB - Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

KW - KPC

KW - Meropenem

KW - P orin

KW - Resistance

KW - Vaborbactam

UR - https://www.scopus.com/pages/publications/85088848147

UR - https://www.scopus.com/pages/publications/85088848147#tab=citedBy

U2 - 10.1093/cid/ciz1131

DO - 10.1093/cid/ciz1131

M3 - Article

C2 - 31738396

AN - SCOPUS:85088848147

SN - 1058-4838

VL - 71

SP - 667

EP - 671

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 3

ER -

Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this